May 19, 2017 11:05 AM EDTUpdated May 19, 08:46 PM
News Briefing

Astel­las, Pfiz­er scrap a PhI­II breast can­cer study us­ing Xtan­di; New $30M fund will back Is­raeli biotech star­tups

Shehla Shakoor

Managing Director

→ NanoS­tring Tech­nolo­gies notes in an SEC fil­ing that Astel­las and Pfiz­er have de­cid­ed to ter­mi­nate the late-stage EN­DEAR tri­al, which the com­pa­ny was …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times